GSK (GSK) partners with Sino Biopharmaceutical to launch bepirovirsen in China
GSK plc has forged an exclusive strategic collaboration with Sino Biopharmaceutical's SBP Group, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), to expedite the introduction of bepirovirsen in mainland China. Bepirovirsen is a prospective first-in-class treatment for chronic hepatitis B, currently undergoing priority regulatory review in the country.
Under the terms of the agreement, CTTQ will assume responsibility for the importation, distribution, hospital access, and promotional activities across its extensive network of over 5,000 medical centres in China. GSK will maintain marketing authorisation and oversee regulatory, quality, pharmacovigilance, and global medical strategy for the treatment. The collaboration aims to accelerate market entry for bepirovirsen, which is presently under priority regulatory review in China, according to a statement published on 11 May 2026.
The strategic alliance underscores GSK's commitment to expanding its pharmaceutical footprint in the significant Chinese market. GSK plc shares were up 0.1% to 1,888p in London trading on Thursday, 14 May 2026, from a previous close of 1,886p.
Why a Strategic Alliance Speeds Up Drug Access
GSK plc is a global pharmaceutical company focused on developing, manufacturing, and distributing a wide range of medicines, vaccines, and consumer healthcare products. Their business revolves around discovering new treatments for diseases, bringing them through rigorous clinical trials, and then making them available to patients and healthcare systems worldwide. They generate revenue by selling these essential health solutions to individuals, hospitals, and governments across various markets.
Today's slight movement in GSK's shares stems from a strategic collaboration designed to accelerate market entry for a new drug, bepirovirsen, in mainland China. Rather than building out its own extensive distribution and promotional network from scratch, GSK is partnering with Sino Biopharmaceutical's CTTQ. This alliance leverages CTTQ's existing reach across over 5,000 medical centres in China, significantly reducing the time and cost associated with commercialising bepirovirsen, a prospective first-in-class treatment for chronic hepatitis B that is already under priority regulatory review.
This move to secure a robust local partner for rapid commercialisation has seen GSK plc shares rise 0.1% today. The stock is currently trading at 1,888p, up from its previous close of 1,886p.
Think of it like a global logistics company needing to deliver a time-sensitive, high-value package to every corner of a vast country. Instead of building new roads, warehouses, and delivery teams, they partner with an established domestic courier service that already has the infrastructure and local expertise in place. This partnership ensures the package reaches its destination much faster and more efficiently, capitalising on existing networks for swift delivery.
GSK plc
GSK plc (GSK) operates as a diversified healthcare company, developing and marketing a broad portfolio of pharmaceutical products, vaccines, and consumer health goods across the UK, US, and international markets. Its operations are structured into four key segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The pharmaceutical division focuses on therapeutic areas including respiratory, HIV, oncology, and immunology, while its consumer health offerings span wellness, oral health, nutrition, and skin health categories, available in various formats such as tablets, creams, and dental care products. GSK engages in numerous collaborations with partners like 23andMe, Novartis, and Sanofi SA, alongside strategic partnerships with IDEAYA Biosciences and Vir Biotechnology. Formerly GlaxoSmithKline plc, the company rebranded in May 2022 and has roots dating back to 1715, with its headquarters located in Brentford, United Kingdom.